AU2004245484A1 - Neuroprotective benzoate and benzamide compounds - Google Patents

Neuroprotective benzoate and benzamide compounds Download PDF

Info

Publication number
AU2004245484A1
AU2004245484A1 AU2004245484A AU2004245484A AU2004245484A1 AU 2004245484 A1 AU2004245484 A1 AU 2004245484A1 AU 2004245484 A AU2004245484 A AU 2004245484A AU 2004245484 A AU2004245484 A AU 2004245484A AU 2004245484 A1 AU2004245484 A1 AU 2004245484A1
Authority
AU
Australia
Prior art keywords
alkyl
cycloalkyl
compound
procaine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004245484A
Other languages
English (en)
Other versions
AU2004245484A2 (en
Inventor
Janet Greeson
Laurent Lecanu
Vassilios Papadopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Samaritan Pharmaceuticals Inc
Original Assignee
Georgetown University
Samaritan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, Samaritan Pharmaceuticals Inc filed Critical Georgetown University
Publication of AU2004245484A1 publication Critical patent/AU2004245484A1/en
Publication of AU2004245484A2 publication Critical patent/AU2004245484A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2004245484A 2003-06-02 2004-05-20 Neuroprotective benzoate and benzamide compounds Abandoned AU2004245484A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47496403P 2003-06-02 2003-06-02
US60/474,964 2003-06-02
US47564203P 2003-06-04 2003-06-04
US60/475,642 2003-06-04
US47864803P 2003-08-01 2003-08-01
US60/478,648 2003-08-01
US56686904P 2004-04-30 2004-04-30
US60/566,869 2004-04-30
PCT/US2004/016036 WO2004108666A2 (en) 2003-06-02 2004-05-20 Neuroprotective benzoate and benzamide compounds

Publications (2)

Publication Number Publication Date
AU2004245484A1 true AU2004245484A1 (en) 2004-12-16
AU2004245484A2 AU2004245484A2 (en) 2004-12-16

Family

ID=33514878

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004245484A Abandoned AU2004245484A1 (en) 2003-06-02 2004-05-20 Neuroprotective benzoate and benzamide compounds

Country Status (6)

Country Link
US (2) US20060167108A1 (enExample)
EP (1) EP1628649A4 (enExample)
JP (1) JP2006526634A (enExample)
AU (1) AU2004245484A1 (enExample)
CA (1) CA2561452A1 (enExample)
WO (1) WO2004108666A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4949558B2 (ja) 1999-03-23 2012-06-13 ハイバーネーション・セラピューティクス・グローバル・リミテッド 臓器の停止、保護、及び保存
CA2559972A1 (en) * 2004-03-18 2005-09-29 Samaritan Pharmaceuticals, Inc. Benzamide and benzoate anti-hiv compounds
CN101022806A (zh) * 2004-04-15 2007-08-22 萨马里坦药品公司 （4－烷基哌嗪基）（苯基）甲酮在治疗阿尔茨海默病中的应用
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
KR101425579B1 (ko) 2006-05-29 2014-08-13 하이버네이션 테라퓨틱스 리미티드 개선된 조직 유지법
WO2008011670A1 (en) 2006-07-25 2008-01-31 Hibernation Therapeutics Limited Trauma therapy
US20100119554A1 (en) 2007-03-02 2010-05-13 Hibernation Therapeutics Limited Transplants
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
EP2219442A4 (en) * 2007-07-25 2012-05-02 Hibernation Therapeutics Ltd IMPROVED ORGAN PROTECTION, IMPROVED ORGAN CONSERVATION AND IMPROVED ORGAN RECOVERY
WO2014051398A1 (ko) * 2012-09-28 2014-04-03 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
AU2014292827A1 (en) 2013-07-17 2016-02-04 Hibernation Therapeutics, A Kf Llc A method for organ arrest, protection and preservation and reducing tissue injury

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
JPH1033087A (ja) * 1996-07-23 1998-02-10 Koichi Tanaka グルタミン酸トランスポーター遺伝子機能欠損非ヒト動物
JPWO2003035641A1 (ja) * 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体

Also Published As

Publication number Publication date
CA2561452A1 (en) 2004-12-16
US20090286876A1 (en) 2009-11-19
EP1628649A2 (en) 2006-03-01
US20060167108A1 (en) 2006-07-27
EP1628649A4 (en) 2010-06-02
WO2004108666A2 (en) 2004-12-16
WO2004108666A3 (en) 2005-03-31
JP2006526634A (ja) 2006-11-24
AU2004245484A2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
US20090286876A1 (en) Neuroprotective benzoate and benzamide compounds
CN102781436B (zh) 纤维肌痛综合征的治疗方法
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
US20100323987A1 (en) Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20090197891A1 (en) Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
JP2021528495A (ja) ケタミンを含む新規製剤
CA2720987A1 (en) Dosages and methods for the treatment of cancer
HK1218388A1 (zh) 奧那司酮多晶型形式和使用方法
JP2006526634A5 (enExample)
JP2009538822A5 (enExample)
JP2009538822A (ja) 静脈におけるウイルスの治療
JP5469779B2 (ja) 多発性骨髄腫の治療のための組成物および方法
US20090306050A1 (en) Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
JP2005060311A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
AU2005223659A2 (en) Benzamide and benzoate anti-HIV compounds
HK40067920B (en) Vafidemstat for the treatment of non-aggressive symptoms of borderline personality disorder
HK40067920A (en) Vafidemstat for the treatment of non-aggressive symptoms of borderline personality disorder
WO2009104152A1 (en) Combination treatment for ovarian cancer
KR20200099153A (ko) 외상 후 증후군 장애의 치료
MXPA01007833A (es) Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria.
HK1103282A1 (zh) 用於治疗下泌尿道病症的α-氨基酰胺衍生物
HK1103282B (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
TH139656A (th) เอสเทอร์โพรดรักซ์-)Ester-Pro-drugs) ของ [3-(1-(1H-อิมิดาซอล-4-อิล(เอทธิล (-2-เมทธิลฟีนิล] เมทธานอลสำหรับการรักษาโรคผิวหนัง และสภาวะทางผิวหนัง
WO2009104150A1 (en) Combination comprising bosentan for treating ovarian cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 DEC 2005

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period